194 related articles for article (PubMed ID: 19811253)
1. Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women.
de Villiers TJ
Climacteric; 2009; 12 Suppl 1():108-11. PubMed ID: 19811253
[TBL] [Abstract][Full Text] [Related]
2. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Hadji P
Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
[TBL] [Abstract][Full Text] [Related]
3. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
Archer DF
Menopause; 2011 Jan; 18(1):6-7. PubMed ID: 21173718
[No Abstract] [Full Text] [Related]
4. Another selective estrogen-receptor modulator for osteoporosis.
Becker C
N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
[No Abstract] [Full Text] [Related]
5. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
Calaf Alsina J; Coronado MartÃn PJ
Med Clin (Barc); 2013 Mar; 140(6):266-71. PubMed ID: 23276611
[TBL] [Abstract][Full Text] [Related]
6. Lasofoxifene in postmenopausal women with osteoporosis.
Cummings SR; Ensrud K; Delmas PD; LaCroix AZ; Vukicevic S; Reid DM; Goldstein S; Sriram U; Lee A; Thompson J; Armstrong RA; Thompson DD; Powles T; Zanchetta J; Kendler D; Neven P; Eastell R;
N Engl J Med; 2010 Feb; 362(8):686-96. PubMed ID: 20181970
[TBL] [Abstract][Full Text] [Related]
7. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
8. Use of SERMs for treatment in postmenopausal women.
Pinkerton JV; Thomas S
J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
[TBL] [Abstract][Full Text] [Related]
9. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease.
Mosca L; Grady D; Barrett-Connor E; Collins P; Wenger N; Abramson BL; Paganini-Hill A; Geiger MJ; Dowsett SA; Amewou-Atisso M; Kornitzer M
Stroke; 2009 Jan; 40(1):147-55. PubMed ID: 18948611
[TBL] [Abstract][Full Text] [Related]
10. New selective estrogen receptor modulators (SERMs) in development.
Silverman SL
Curr Osteoporos Rep; 2010 Sep; 8(3):151-3. PubMed ID: 20603714
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Lewiecki EM
J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
[TBL] [Abstract][Full Text] [Related]
12. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications.
Vogelvang TE; van der Mooren MJ; Mijatovic V
Treat Endocrinol; 2004; 3(2):105-15. PubMed ID: 15743106
[TBL] [Abstract][Full Text] [Related]
14. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.
Vogelvang TE; van der Mooren MJ; Mijatovic V; Kenemans P
Drugs; 2006; 66(2):191-221. PubMed ID: 16451093
[TBL] [Abstract][Full Text] [Related]
15. An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis.
Komm BS; Chines AA
Maturitas; 2012 Mar; 71(3):221-6. PubMed ID: 22196312
[TBL] [Abstract][Full Text] [Related]
16. Lasofoxifene in osteoporosis and its place in therapy.
Swan VJ; Hamilton CJ; Jamal SA
Adv Ther; 2010 Dec; 27(12):917-32. PubMed ID: 21080249
[TBL] [Abstract][Full Text] [Related]
17. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
18. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health.
Draper MW
Ann N Y Acad Sci; 2003 Nov; 997():373-7. PubMed ID: 14644844
[TBL] [Abstract][Full Text] [Related]
19. The selective estrogen receptor modulators in breast cancer prevention.
Li F; Dou J; Wei L; Li S; Liu J
Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.
Duvernoy CS; Yeo AA; Wong M; Cox DA; Kim HM
J Womens Health (Larchmt); 2010 Aug; 19(8):1459-65. PubMed ID: 20626269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
